

Case Completeness in Switzerland

Incidence period 2005 – 2010

Matthias Lorez
Coordination Centre
Foundation NICER
Zurich, Switzerland

www.nicer.org




SWITZERLAND (CH) 8 Million Pop.

26 Cantons

Swiss registration coverage (2010):

5.3 Million (68% of total)





Registry	Cancer reportable by law ?	DCN / DCO [%]
Α	No	2.5 / 1.2
В	No	1.5 / 0.4
С	No	2.5 / 0.6
D	No	2.7 / 0.3
E	No	2.3 / 0.2

Information abstracted from Questionaires submitted to CI-V vol. 9 and 10.



Methods

ICD-10:

C00-14, C16, C18-21, C22, C25, C33-34, C43, C50, C53-55, C56, C61, C64, C67, C69-72, C82-86_96, C90, C91-95, C00-43_45-97

CL (C91.1_ C92.1)

Mortality/Incidence Ratio versus 1- Relative Survival¹- Plot

- Semi-quantitative
- Age-standardized M- and I-Rates (2005-2010)
- RS: complete type and age-standardized (ICSS) (2005-2010)

Flow Method²

Quantitative



WP3 Working group (Zanetti et al.)

References:

- 1. Parkin and Bray (2009). Evaluation of data quality in the cancer registry: Principles and methods Part II. Completeness. *Eur J Cancer* **45**, 756-764.
- 2. Bullard et al. (2000). Completeness of cancer registration: a new method for routine use. Br J Cancer 82, 1111-1116.



Mortality/Incidence Ratio versus 1-RS Plot

5 year (cumulative) $RS = \frac{\% \text{ alive 5 years after diagnosis (specific disease)}}{\% \text{ expected alive with background mortality *}}$

^{*} Cohort of general population matched by sex, age, calendar time, language region (yearly lifetables with annual prob. of death).



Quality of Swiss Vital Statistics:

Percentage of cancer deaths assigned to ill-defined or less specific cancer codes.


Source: Registered single primary cases who died 2001-10 (100%)

Diagnosis	% III-defined «C» COD*	% other «C» COD	Total (N)
C00-14	1.5	5.8	753
C16	0.8	5.5	932
C18-21	0.9	3.4	2890
C22	1.0	1.6	1163
C25	0.7	2.5	1344
C33-34	1.5	1.0	4197
C43	1.4	2.2	494
C50	0.5	1.1	2473
C53-55	0.8	4.1	606
C56	1.8	2.5	598
C61	0.9	1.5	2332
C64	0.4	3.0	494
C67	1.4	6.4	849
C69-72	0.2	2.6	614
C82-86,96	0.8	6.4	801
C90	0.5	0.5	426
C91-95	0.3	3.0	672

^{*}C76-80,97: ill-defined, secondary and unspecified; independent (primary) multiple sites



Mortality/Incidence Ratio versus 1- 5year Relative Survival Plot





Flow method

(Bullard et al. 2000; Silcocks and Robinson 2007)

Two reasons for a patient to remain unregistered at t_i after diagnosis (t_0):

I. Patient is <u>missing</u>, but remains potentially registerable during life.
Patient is <u>still alive</u> at t_i but <u>not yet registered</u>:

$$M(t_i) = s(t_i) * u(t_i)$$

II. Patient became permanentely <u>lost</u>.
Patient has died in the interval t_{i-1} and t_i, has not been registered during life and lacked <u>mentioning of cancer in the DCs</u>:

$$L(t_i) = \left[s(t_i) - s(t_{i-1}) \right] * u(t_i) * \left[1 - m(t_i) \right]$$

III. Case completeness after *n* intervals:


$$C(t_n) = 1 - M(t_n) - \sum_{i=1}^{n} L(t_i)$$

Assumptions:

- All DCs with cancer mentioned are sent to registry
- Registration after death occures only through DCs




Data extracted for simple time-dependent Probabilities (Flow method)





Case completeness 5 years after diagnosis (Flow method)





Conclusions

	M/I vs 1-RS Plot	Flow method
Weekness	 Inconclusive findings (many assumptions) Complex calculations (RS) 	Underemployed (very few publications)
Strength	 M/I and RS are routinely monitored 	 Simple calculations (OS) Accounts for registration dynamics

Swiss case completeness 5 years after diagnosis:

High: most cancer sites

Less than optimal: C22 and C61

Under-registered: CLL / CML



Thank you for your kind attention!

Thanks to co-investigators:

Dr. Andrea Bordoni Cancer Registry of Ticino

Dr. Christine Bouchardy Cancer Registry of Geneva

Dr. Silvia Ess Cancer Registry of St. Gallen-Appenzell

Cancer Registry of Graubünden-Glarus

Dr. Isabelle Konzelmann Cancer Registry of Valais

Prof. Kerri Clough-Gorr ISPM University of Berne

Please send all suggestions and comments to: <u>ML@nicer.org</u>

NICER is funded by:

Swiss Federal Office of Public Health (FOPH)

